Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Neutral rating on Agios Pharmaceuticals (AGIO) and raises the price target from $29 to $33.

May 03, 2024 | 3:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Neutral rating on Agios Pharmaceuticals and raises the price target from $29 to $33.
The increase in price target by Goldman Sachs suggests a positive outlook on the stock's value, potentially leading to short-term price appreciation. However, the Neutral rating indicates that the stock might not outperform the market significantly.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100